Among patients with non-small-cell lung cancer and a high tumor mutational burden, significantly longer PFS occurred with combination therapy of PD-1 antibody nivolumab and CTLA-4 antibody ipilimumab than with chemotherapy6. This evidence concerns the gene CTLA4 and neoplasm.